Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:24 AM
Ignite Modification Date:
2025-12-25 @ 4:24 AM
NCT ID:
NCT07198620
Eligibility Criteria:
Inclusion Criteria:
* Voluntarily participate in the study and provide signed informed consent.
* Have histologically or cytologically confirmed locally advanced or metastatic NSCLC, classified according to the IASLC 8th edition Lung Cancer TNM Staging System.
* Carry a confirmed KRAS G12C mutation via molecular testing.
* Have received at least one dose of oral IBI-351 treatment between August 2024 and August 2025.
Exclusion Criteria:
* Histologically or cytologically confirmed mixed NSCLC with a predominant small cell or squamous cell carcinoma component.
* Presence of EGFR sensitizing mutations, ALK rearrangements, ROS1 fusions, or other genomic alterations for which NMPA has approved first-line NSCLC therapies.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT07198620
Study Brief:
Protocol Section:
NCT07198620